Cocrystal Pharma, Inc. COCP
Nov 4, 2026, 11:57 AM EST
- YTD
- +6.12%
- 1 year
- +0.97%
- Market cap
- 20.03M
- EPS (ttm)
- -0.76
- Shares out
- 10.17M
- Forward P/E
- -1.22
- YTD return
- +6.12%
- 1-year return
- +0.97%
- Volume
- 16.39K
- Avg volume
- 50.36K
- Open
- 1.07
- Previous close
- 1.07
- Day's range
- 1.01 – 1.09
- 52-week range
- 0.76 – 2.03
- Beta
- 1.45
- Price target
- 8.00 (+669.2%)
- Earnings date
- Aug 14, 2024
YTD +0.02 (+2.02%)
Key statistics
- Enterprise value
- 6.02M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -9.71M
- Total cash
- 18.14M
- Total debt
- 1.78M
- Return on equity
- -68.86%
- Short % of float
- 0.03%
- 50-day average
- 1.96
- 200-day average
- 1.91
Analyst view
- Target (low)
- 7.00
- Target (mean)
- 8.00
- Target (high)
- 10.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.56.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.57 | -0.49 | +0.08 | +14.04% |
| Aug 14, 2024 | Jun 1, 2024 | -0.51 | -0.53 | -0.02 | -3.92% |
| Aug 14, 2024 | Jun 1, 2024 | -0.51 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.54 | -0.39 | +0.15 | +27.78% |
| May 13, 2024 | Mar 1, 2024 | -0.54 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -0.57 | -0.44 | +0.13 | +22.81% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jan 3, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 4, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 4, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cocrystalpharma.com
News
Xeris Biopharma (NASDAQ:XERS) vs. Cocrystal Pharma (NASDAQ:COCP) Head-To-Head Contrast 
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment 
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors 
Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K 
Cocrystal Pharma Secures $5M Investment From OPKO Health To Advance Norovirus Program Toward Phase 1b Data 
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health 
Financial Contrast: Cocrystal Pharma (NASDAQ:COCP) vs. Zevra Therapeutics (NASDAQ:ZVRA) 
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer 
Watching Cocrystal Pharma; Zacks-Small Cap Research Gives Stock $8 Price Valuation - Cocrystal Pharma's Direct-Acting Antivirals Demonstrate Pan-Viral Activity Against Multiple Viruses, Including Hantavirus, Bunyavirus And Influenza
Your note
Sign in to keep a note on COCP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Oct 8, 2024 | 1,346,940 |
| HASSAN FRED | Director | Stock Award(Grant) | Oct 8, 2024 | 1,023,300 |
| JAPOUR ANTHONY J M.D. | Director | Stock Award(Grant) | Oct 8, 2024 | 14,924 |
| KORNBERG ROGER D | Director | Stock Award(Grant) | Oct 8, 2024 | 67,878 |
| LEE SAM | Chief Executive Officer | Stock Award(Grant) | Oct 8, 2024 | 76,355 |
| MARTIN JAMES JOSEPH | Chief Executive Officer | Stock Award(Grant) | Oct 8, 2024 | 40,569 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.71% | 275,656 | 741.51K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.28% | 130,028 | 349.77K | Sep 29, 2024 |
| Blackrock Inc. | 0.72% | 73,746 | 198.38K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.65% | 66,260 | 178.24K | Sep 29, 2024 |
| Morgan Stanley | 0.58% | 59,300 | 159.52K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.37% | 37,800 | 101.68K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.88% | 191,359 | 514.75K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.75% | 76,721 | 206.38K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 38,371 | 103.22K | Oct 30, 2024 |
| DFA U.S. Targeted Value Portfolio | 0.09% | 9,487 | 25.52K | Jul 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 8,667 | 23.31K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 8,526 | 22.93K | Oct 30, 2024 |